Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 14/01/2025 GMT			5-day change	1st Jan Change
267.10 ^USD	-1.14%		+1.92%	+2.48%

01-14	Amgen Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:00 PM
01-10	Wells Fargo Cuts Price Target on Amgen to $280 From $335, Maintains Equalweight Rating	MT

Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results

November 26, 2024 at 05:19 pm

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Amgen Inc.

Amgen Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:00 PM	01-13
Wells Fargo Cuts Price Target on Amgen to $280 From $335, Maintains Equalweight Rating	01-10	MT
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating	01-08	MT
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement with Amgen on Etakafusp Alfa in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer	01-08	CI
Truist Lowers Price Target on Amgen to $298 From $333, Keeps Hold Rating	01-08	MT
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating	01-07	MT
Amgen?s IMDYLLTRA Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom	01-06	CI
European Equities Close Mostly Higher in Tuesday Trading; EU Withholds Over $1 Billion From Hungary	12-31	MT
Amgen's Tarlatamab Approved by UK Regulator to Treat Lung Cancer	12-31	MT
Sector Update: Health Care Stocks Advance Late Afternoon	12-23	MT
Sector Update: Health Care	12-23	MT
Eli Lilly, Amgen Sue HHS for Unlawful Certifications of Drug Discount Program Recipients	12-23	MT
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients	12-23	MT
Top Midday Stories: Novo Nordisk Shares Drop After Obesity Treatment Falls Short of Expectations; CFPB Sues 3 Big Banks Over Alleged Zelle Fraud	12-20	MT
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations	12-20	MT
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating	12-19	MT
Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug	12-18	MT
Akari Therapeutics, plc Announces Board Changes	12-18	CI
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating	12-17	MT
Amgen Inc. Announces Blincyto (Blinatumomab) Added to Chemotherapy Significantly Improves Survival in Newly Diagnosed Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)	12-07	CI
Amgen Plans $1 Billion North Carolina Manufacturing Plant	12-05	DJ
Amgen Expanding in North Carolina With $1 Billion New Manufacturing Site	12-05	MT
Amgen Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 09:30 AM	12-05
Amgen Announces $1 Billion Manufacturing Expansion in North Carolina	12-05	CI
Amgen Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 10:00 AM	12-04

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Employees

26,700

Sector

Pharmaceuticals

Calendar

04/02/2025 - Q4 2024 Earnings Release

More about the company